Catheter Precision Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
VTAK$0.15-0.7%Stored close · as of Oct 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(11,015) | $(69,903) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Loss on impairment of goodwill | — | 60,934 |
| Depreciation and amortization | 1,578 | 1,558 |
| Stock-based compensation | 36 | 1,222 |
| Change in fair value of royalties payable | 2,823 | (5,333) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 30 | 25 |
| Inventories | (7) | (12) |
| Prepaid expenses and other assets | 108 | 913 |
| Operating lease right-of-use assets and lease liabilities | (1) | 5 |
| Current portion of royalties payable | 17 | — |
| Accounts payable | 244 | (849) |
| Accrued expenses | (236) | (7,092) |
| Interest payable to related parties | 16 | (198) |
| Net cash used in operating activities | (6,407) | (18,730) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (67) | (58) |
| Cash acquired as part of business combination | — | 15 |
| Net cash used in investing activities | (67) | (43) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock and warrants | — | 238 |
| Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs | 2,612 | — |
| Proceeds from notes payable due to related parties | 1,500 | — |
| Payment on note payable | (184) | |
| Proceeds from note payable | 249 | — |
| Proceeds from exercise of warrants | — | 1,326 |
| Payments of costs related to the warrant repricing | — | (181) |
| Payments of convertible promissory notes and accrued interest | — | (250) |
| Proceeds from the private placement of securities | — | 8,000 |
| Payments of offering costs related to the private placement of securities | — | (640) |
| Net cash provided by financing activities | 4,177 | 8,493 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (2,297) | (10,280) |
| CASH AND CASH EQUIVALENTS, beginning of period | 3,565 | 15,859 |
| CASH AND CASH EQUIVALENTS, end of period | $1,268 | $5,579 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash payments for interest | $25 | $198 |
| SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Non-cash consideration for Catheter acquisition | $— | $72,544 |
| Property and equipment reclassified from inventories | $19 | $— |
| Conversion of Series A Convertible Preferred Stock for common stock | $— | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.